Maurizio Cavallari

Mestre, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

Journal: EClinicalMedicine

Published: April 09, 2026

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Venetoclax in Combination With Chemo-Immunotherapy in Richter Transformation: A Real-Life Experience.

Journal: Hematological oncology

Published: February 14, 2026

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.

Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints.

Journal: Cancer journal (Sudbury, Mass.)

Published: August 16, 2021

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results.

Journal: Genes

Published: November 03, 2020

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation.

Journal: Haematologica

Published: September 10, 2020

In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.

In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.

Journal: British journal of haematology

Published: April 04, 2020

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Journal: Cancer medicine

Published: March 30, 2020

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Journal: British journal of cancer

Published: March 27, 2019

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia.

Journal: Oncotarget

Published: April 05, 2018

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Journal: British journal of haematology

Published: October 23, 2017

In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.

In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.

Journal: Blood

Published: April 28, 2017

"Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia".

"Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia".

Journal: Leukemia research reports

Published: October 11, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026